Gastens, Viktoria; Del Giovane, Cinzia; Anker, Daniela; Feller, Martin; Syrogiannouli, Lamprini; Schwab, Nathalie; Bauer, Douglas C; Rodondi, Nicolas; Chiolero, Arnaud (2021). Development and validation of a life expectancy estimator for multimorbid older adults: a cohort study protocol. BMJ open, 11(8), e048168. BMJ Publishing Group 10.1136/bmjopen-2020-048168
|
Text
Gastens__BMJ_Open_2021.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (325kB) | Preview |
BACKGROUND
Older multimorbid adults have a high risk of mortality and a short life expectancy (LE). Providing high-value care and avoiding care overuse, including of preventive care, is a serious challenge among multimorbid patients. While guidelines recommend to tailor preventive care according to the estimated LE, there is no tool to estimate LE in this specific population. Our objective is therefore to develop an LE estimator for older multimorbid adults by transforming a mortality prognostic index, which will be developed and internally validated in a prospective cohort.
METHODS AND ANALYSIS
We will analyse data of the Optimising Therapy to Prevent Avoidable Hospital Admissions in Multimorbid Older People cohort study in Bern, Switzerland. 822 participants were included at hospitalisation with age of 70 years or older, multimorbidity (three or more chronic medical conditions) and polypharmacy (use of five drugs or more for >30 days). All-cause mortality will be assessed during 3 years of follow-up. We will apply a flexible parametric survival model with backward stepwise selection to identify the mortality risk predictors. The model will be internally validated using bootstrapping techniques. We will derive a point-based risk score from the regression coefficients. We will transform the 3-year mortality prognostic index into an LE estimator using the Gompertz survival function. We will perform a qualitative assessment of the clinical usability of the LE estimator and its application. We will conduct the development and validation of the mortality prognostic index following the Prognosis Research Strategy (PROGRESS) framework and report it following the Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) statement.
ETHICS AND DISSEMINATION
Written informed consent by patients themselves or, in the case of cognitive impairment, by a legal representative, was required before enrolment. The local ethics committee (Kantonale Ethikkommission Bern) has approved the study. We plan to publish the results in peer-reviewed journals and present them at national and international conferences.
Actions (login required)
 |
Edit item |